Share on twitter
Share on LinkedIn
Share on Facebook
Email to a friend
Print page
This CEU Statement provides guidance to healthcare professionals in response to a letter circulated by MSD (manufacturer of Nexplanon®) to healthcare professionals in the UK about updated guidance regarding the recommended Nexplanon® insertion site.
This statement is a response to a study published in the New England Journal of Medicine, suggests that a 52mg levonorgestrel-releasing intrauterine system (LNG-IUS) is non-inferior to a T380A copper IUD (Cu-IUD) for emergency contraception (EC).
This statement notes that the Levosert® 52mg LNG-IUS has been licensed for contraceptive use for 6 years. Levosert remains licensed for 5 years for management of heavy menstrual bleeding and is not licensed for endometrial protection as part of HRT.
This statement is a response to a new paper published in BMJ Evidence Based Medicine Journal suggesting that antibiotics may lessen the effectiveness of hormonal contraception.
This FSRH CEU Statement considers the risk of thromboembolism associated with Covid-19 infection, and suggests a pragmatic approach to use of combined hormonal contraception during the Covid-19 pandemic
The FSRH CEU summarizes and comments on the Cameron, et al “Bridge-It” study, which found that women receiving levonorgestrel emergency contraception from a pharmacy are more likely to be using effective ongoing contraception if they are given a three-month supply of progestogen-only pill and facilitated access to local SRH services.
“The effects on ovarian activity of delaying versus immediately restarting combined oral contraception after missing three pills and taking ulipristal acetate 30 mg” The journal Contraception recently published a study investigating timing of combined oral contraceptive pill (COC) restart after missed pills and use of ulipristal acetate emergency contraception (UPA-EC). The FSRH CEU responds to this study and advises where guidance does—and does not—change.
This statement is a response to new advice from the MHRA regarding use of cyproterone acetate and risk of meningioma.
This statement addresses the issues faced by the health and care workforce before and during the COVID-19 pandemic.
FSRH CEU has produced an information sheet to support the provision of contraception by maternity services after childbirth during the Covid-19 outbreak.
At present, to reduce risk of coronavirus transmission, non-essential face-to-face contact with healthcare providers is being minimised where possible. Replacement procedures for long-acting reversible contraceptive (LARC) devices that have recently expired are non-essential. This FSRH CEU statement provides recommendation on extended use of the etonogestrel implant and 52mg levonorgestrel-releasing intrauterine system during COVID restrictions.
